Apomine

Overview

Apomine (SR-45023A) is an orally active antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis. Apomine can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) . Apomine can also inhibit the growth of various types of cancer cells, including lung cancer , colon cancer , breast cancer , and skin cancer . Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer , liver cancer , ovarian cancer , and breast cancer .

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HMG-CoA Reductase (HMGCR) | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-19671
• CAS No.: 126411-13-0
• Molecular Formula: C28H52O7P2
• Molecular Weight: 562.66
• Purity: 99.67%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2 mg/mL (3.55 mM); Clear solution
• Availability: In-stock

Source

Original product source